Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FABP1 | P07148 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7625960 | 0.83 | NT5E (0.53) | CYP1A2CISD1NT5EGLAGAA | |
| SCHEMBL8020759 | 0.80 | CISD1 (0.41) | CYP1A2F10CISD1NT5EGLA | |
| SCHEMBL10606946 | 0.77 | CISD1 (0.36) | CYP1A2F10CISD1GLAGAA | |
| SCHEMBL11436483 | 0.76 | NT5E (0.40) | CYP1A2F10CISD1NT5ETYR | |
| SCHEMBL11124965 | 0.76 | F10 (0.41) | CYP1A2F10CISD1GLAGAA | |
| SCHEMBL11028747 | 0.73 | GAA (0.47) | CYP1A2F10CISD1GLAGAA | |
| SCHEMBL7755552 | 0.73 | GLA (0.44) | CYP1A2F10CISD1GLAGAA | |
| SCHEMBL6575801 | 0.72 | GAA (0.44) | CYP1A2F10CISD1GLAGAA | |
| SCHEMBL10787453 | 0.72 | NSD2 (0.45) | F10CISD1NT5EGLAGAA | |
| SCHEMBL10783995 | 0.72 | NT5E (0.45) | F10CISD1NT5EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232193-B1 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BIOMARIN PHARM INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210025874-A1 | METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210017570-A1 | DETECTION OF OLIGOSACCHARIDES | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10793894-B2 | Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10683530-B2 | Detection of oligosaccharides | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10677786-B2 | Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190249224-A1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10260084-B2 | Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2900831-B1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | BIOMARIN PHARM INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2376916-B1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | BIOMARIN PHARM INC (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2010078514-A2 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2190983-A1 | MODIFIED XYLAN PRODUCTION | Cambridge Enterprise Limited (GB) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009037502-A1 | MODIFIED XYLAN PRODUCTION | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| US-20070167608-A1 | Sugar chain structure profiling techniques | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2007-07-19 | — | — | US | disclosed |
| US-6086640-A | DYEING CELLULOSE WITH FIBER REACTIVE BLUE DYE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0964033-A1 | FORMAZAN COMPOUNDS AND METHOD OF DYEING THEREWITH | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5403922-A | Surfactants, vesicular agents | STEPAN EUROPE (FR) | 1995-04-04 | — | — | US | disclosed |
| EP-0031099-B1 | COMPOUNDS WITH REACTIVE RESTS AND THEIR USE IN DYEING FIBRES | BASF Aktiengesellschaft (DE) | 1984-07-18 | — | — | EP | disclosed |
| EP-0066714-A2 | Reactive dyestuffs | BASF Aktiengesellschaft (DE) | 1982-12-15 | — | — | EP | disclosed |
| EP-0031099-A2 | Compounds with reactive rests and their use in dyeing fibres | BASF Aktiengesellschaft (DE) | 1981-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017570-A1 | DETECTION OF OLIGOSACCHARIDES | MAN2B1, MAN1B1, MAN2B2 | CYP1A2 4537/4885F10 2288/4885CISD1 2245/4885 |
| US-10683530-B2 | Detection of oligosaccharides | MAN2B1, MAN1B1, MAN2B2 | CYP1A2 4537/4885F10 2288/4885CISD1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.